The Galactocerebrosidase pipeline drugs market research report outlays comprehensive information on the Galactocerebrosidase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Galactocerebrosidase pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Galactocerebrosidase - Drugs In Development, 2024

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers products from therapy areas such as Central Nervous System which include the indications Globoid Cell Leukodystrophy (Krabbe Disease). It also reviews key players involved in Galactocerebrosidase targeted therapeutics development with respective active and dormant or discontinued products.

The Galactocerebrosidase pipeline targets constitutes close to seven molecules. Out of which, approximately seven molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical, and Discovery stages are 1, 2, and 4 respectively.

Galactocerebrosidase overview

Galactosylceramidase is an enzyme that in humans is encoded by a gene GALC. This enzyme hydrolyzes the galactose ester bonds of galactosylceramide, galactosylsphingosine, lactosylceramide, and monogalactosyldiglyceride. Enzyme with very low activity responsible for the lysosomal catabolism of galactosylceramide, a major lipid in myelin, kidney and epithelial cells of small intestine and colon. Mutations in this gene have been associated with Krabbe disease, also known as globoid cell leukodystrophy.

For a complete picture of Galactocerebrosidase’s drug pipeline, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.